-
公开(公告)号：US20230250161A1
公开(公告)日：2023-08-10
申请号：US18170890
申请日：2023-02-17
CPC分类号： C07K16/18 , G01N33/6896 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N2333/4709 , G01N2800/2821 , G01N2800/52
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US11584791B2
公开(公告)日：2023-02-21
申请号：US17089416
申请日：2020-11-04
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US11492393B2
公开(公告)日：2022-11-08
申请号：US16933792
申请日：2020-07-20
发明人： Peter Seubert , Philip James Dolan, III , Yue Liu , Robin Barbour
摘要： The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US20210130449A1
公开(公告)日：2021-05-06
申请号：US17089416
申请日：2020-11-04
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US10906964B2
公开(公告)日：2021-02-02
申请号：US16097445
申请日：2017-05-02
发明人： Robin Barbour , Philip James Dolan, III , Yue Liu
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US10752679B2
公开(公告)日：2020-08-25
申请号：US16092439
申请日：2017-05-02
发明人： Peter Seubert , Philip James Dolan, III , Yue Liu , Robin Barbour
摘要： The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US10654920B2
公开(公告)日：2020-05-19
申请号：US15991998
申请日：2018-05-29
发明人： Stephen Jed Tam , Yue Liu , Robin Barbour , Theodore Yednock , Kenneth Flanagan
IPC分类号： G01N33/574 , C07K16/18 , A61K47/68 , A61K39/00
摘要： The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
-
公开(公告)号：US20180371067A1
公开(公告)日：2018-12-27
申请号：US15991998
申请日：2018-05-29
发明人： Stephen Jed Tam , Yue Liu , Robin Barbour , Theodore Yednock , Kenneth Flanagan
IPC分类号： C07K16/18
摘要： The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
-
公开(公告)号：US09850302B2
公开(公告)日：2017-12-26
申请号：US14329496
申请日：2014-07-11
发明人： Robin Barbour , Yue Liu
CPC分类号： C07K16/26 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/92
摘要： The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
-
公开(公告)号：US09605056B2
公开(公告)日：2017-03-28
申请号：US14049169
申请日：2013-10-08
CPC分类号： C07K16/18 , A61K49/0004 , A61K2039/505 , A61K2039/6056 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , G01N33/6896
摘要： The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.033 秒)
